Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.

"Competing interests MF: Employment/leadership position (University Hospital of Cologne, Head of the GHSG Trial Coordination Centre), honorarium (Celgene, BMS, Takeda, Affimed, Lukon, Janssen). ASJ: No personal disclosures. HK: No personal disclosures. CK: No personal disclosures. TP: No personal disclosures. PJB: Personal disclosures regarding consulting (BeiGene, Takeda), honorarium (BeiGene, BMS, MSD Stemline, Takeda), financing of scientific studies (BeiGene, BMS, MSD, Takeda), other financial relations (Celgene (travel)). MS: No personal disclosures. MV: No personal disclosures. UD: Personal disclosures regarding honorarium (Amgen, Avencell (DSMB activities)). JM: Personal disclosures regarding consulting (MSD) and other financial relations (Travel support Takeda, MSD, BMS). CB: No personal disclosures. VD: No personal disclosures. AR: No personal disclosures. BvT: Personal disclosures regarding consulting (Allogene, BMS/Celgene, Cerus, Incyte, IQVIA, Gilead Kite, Miltenyi, Novartis, Noscendo, Pentixapharm, Roche, Amgen, Pfizer, Takeda, Merck Sharp & Dohme, and Gilead Kite), honorarium (AstraZeneca, BMS, Incyte, Novartis, Roche Pharma AG, Takeda, and Merck Sharp & Dohme), financing of scientific studies (Novartis (Inst), Merck Sharp & Dohme (Inst), and Takeda (Inst)) and other financial relations (Travel support and congress fees: AbbVie, AstraZeneca, Gilead Kite, Merck Sharp & Dohme, Roche, Takeda, and Novartis). MD: No personal disclosures. DAE: Personal disclosures regarding honorarium (Sanofi-Genzyme, Takeda)."

"Funding Open Access funding enabled and organized by Projekt DEAL."